🔗 Share this article

The recently developed medications for gonorrhoea in a generation are being described as a "major milestone" in the fight against drug-resistant strains of the bacteria, according to researchers.

A Global Challenge

Gonorrhoea infections are on the rise around the world, with figures suggesting in excess of 82 million instances annually. Particularly high rates are reported in the African continent and nations within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have reached a historical peak, while infection numbers across Europe in 2023 were triple the level compared to those in 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary advancement in the reality of growing infection rates, increasing antimicrobial resistance and the highly restricted therapeutic options currently available.”

Public health authorities are particularly alarmed about the increase in antibiotic-resistant strains. The global health body has designated it as a "critical concern". A tracking program showed that resistance to primary antibiotics like cefixime and ceftriaxone had risen sharply between 2022 and 2024.

Two New Drugs Gain Authorization

One new antibiotic, marketed under the name a brand name, was cleared by the US FDA in mid-December for combating gonorrhoea. This disease can lead to major issues, including infertility. Experts believe that targeted use of this new drug will help hinder the emergence of superbugs.

Another new antibiotic, developed by the pharmaceutical company GSK, was also approved in concurrent days. This drug, which is also used to treat urinary tract infections, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin stemmed from a innovative non-profit model for drug creation. The non-profit organisation GARDP worked alongside the drug firm Innoviva to see it through.

“This milestone represents a significant shift in the management of superbug gonorrhoea, which up to this point has been staying ahead of medical innovation.”

Research Study Results and Global Access

According to results detailed in a major medical journal, zoliflodacin successfully treated over nine in ten of genital gonorrhoea infections. This places it at an comparable level with the current standard treatment, which uses two antibiotics. The research involved nearly 1,000 volunteers from several countries including the United States, Thailand, South Africa, and European nations.

Under the terms of its collaboration, GARDP has the authority to make available and distribute the drug in a wide range of regions with limited resources.

Doctors treating patients have shared optimism. Having a one-pill regimen such as this is described as a "revolutionary step" for gonorrhoea control. This is viewed as essential to alleviate the strain of the disease for people and to halt the transmission of untreatable gonorrhoea around the world.